SCHEMBL1783311

SCHEMBL1783311

N#CCn1c(=O)n(C2CCCC2)c2nc(Cl)ncc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 8/20 0.48
JAK1 P23458 5/20 0.48
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
CTSS P25774 2/20 0.39
CTSK P43235 2/20 0.39
TNF P01375 2/20 0.37
LITAF Q99732 2/20 0.37
PDE4B Q07343 1/20 0.37
PDE4D Q08499 1/20 0.37
JAK2 O60674 7/20 0.37
PRKDC P78527 4/20 0.36
PIK3CA P42336 3/20 0.36
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CSF1R P07333 1/20 0.34
TTK P33981 1/20 0.34
CCNT1 O60563 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28722191 0.90 JAK3 (0.47) JAK3JAK1JAK2PRKDCPIK3CA
SCHEMBL1781770 0.84 TNF (0.48) OPRM1OPRK1OPRL1TNFLITAF
SCHEMBL29029712 0.78 JAK2 (0.43) JAK3JAK1JAK2PRKDCPIK3CA
SCHEMBL1780155 0.77 PRKDC (0.52) PRKDCPIK3CACSF1RTTKCDK2
SCHEMBL15795275 0.77 GRIN1 (0.44) CDK4CCND1
SCHEMBL20299336 0.76 PRKDC (0.53) PRKDCPIK3CACSF1RTTKCDK2
Iodomethane SCHEMBL3722711 0.75 PRKDC (0.50) PRKDCPIK3CACSF1RTTKCDK2
SCHEMBL1693556 0.75 LMNA (0.37) JAK3TNFLITAFPDE4BPDE4D
SCHEMBL29029715 0.75 TNF (0.40) JAK3JAK1OPRM1OPRK1OPRL1
SCHEMBL1782930 0.74 CDK2 (0.52) JAK3JAK1PRKDCCCNT1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-05-19 US disclosed
EP-2212326-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-04 EP disclosed
WO-2009024824-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BUB1, BUB1B, TTBK1 JAK3 1574/4885JAK1 370/4885OPRM1 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.